Join the 'Tardive Dyskinesia' group to help and get support from people like you.
Tardive Dyskinesia News
Related terms: Tardive, Dyskinesia
Teva Announces FDA Approval of Austedo (deutetrabenazine) Tablets for the Treatment of Tardive Dyskinesia in Adults
Posted 30 Aug 2017 by Drugs.com
JERUSALEM--(BUSINESS WIRE) August 30, 2017 --Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved Austedo (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults. Austedo was previously approved for the treatment of chorea associated with Huntington’s disease in April 2017. Tardive dyskinesia i ...
Posted 25 Aug 2017 by Drugs.com
EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) – Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved Gocovri (amantadine) extended release capsules (previously ADS-5102) for treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. ...
Posted 12 Apr 2017 by Drugs.com
WEDNESDAY, April 12, 2017 – Ingrezza (valbenazine), the first drug to treat adults with the neurological disorder tardive dyskinesia, has been approved by the U.S. Food and Drug Administration. The disorder is characterized by repetitive involuntary movements, usually of the jaw, lips and tongue. Affected people may stick out the tongue, smack the lips, involuntarily move the arms and legs, and ...
Neurocrine Announces FDA Approval of Ingrezza (valbenazine) as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD)
Posted 11 Apr 2017 by Drugs.com
SAN DIEGO, April 11, 2017 /PRNewswire/ – Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved Ingrezza (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD). Ingrezza, a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is the first and only FDA-approved product indicated for the ...
Related Condition Support Groups
Related Drug Support Groups
propranolol, clonidine, ropinirole, pramipexole, bromocriptine, vitamin e, chlordiazepoxide, tetrabenazine, Ingrezza, view more... Austedo, Alpha E, apomorphine, Aquasol E, Amino-Opti-E, Vita-Plus E Natural, valbenazine, Nutr-E-Sol, E-400 Clear, Aquavite-E, Aqua-E, Aqua Gem-E, E-600, E-Gems, deutetrabenazine, E Pherol